Perimenopausal depression: Targeting inflammation and oxidative stress (Review)

Mol Med Rep. 2025 Jun;31(6):161. doi: 10.3892/mmr.2025.13526. Epub 2025 Apr 11.

Abstract

Depressive disorder is a highly disabling condition that affects more than 300 million individuals worldwide, with women affected at a higher rate than men. With the aging of the population, the incidence of perimenopausal depression has risen markedly, seriously jeopardizing women's physical and mental health. Symptoms of perimenopausal depression include feelings of depression, stress, anxiety and endocrine dysfunctions, particularly hypogonadism and senescence. During perimenopause, estrogen and progesterone levels fluctuate erratically, adding to the risk of developing depression associated with perimenopause. As a result of these hormonal changes, proinflammatory mediators are produced and oxidative stress is induced, which finally leads to progressive neuronal damage. The present study mainly reviewed roles of neuroinflammation in perimenopausal depression and explained potential anti‑inflammatory and anti‑oxidative stress mechanisms for clinically effective therapeutic treatment.

Keywords: inflammation; oxidative stress; perimenopausal depression; reactive oxygen species.

Publication types

  • Review

MeSH terms

  • Animals
  • Depression* / drug therapy
  • Depression* / metabolism
  • Female
  • Humans
  • Inflammation* / drug therapy
  • Inflammation* / metabolism
  • Oxidative Stress* / drug effects
  • Perimenopause* / metabolism
  • Perimenopause* / psychology